CDKN1A Antibody (C-term)
Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
United StatesOrdering Information
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanKoreaLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamOthers
(40 western blots)
$ 265.00email & fax$ 251.75online
|Add to cart|
(8 western blots)
$ 95.00email & fax$ 90.25online
|Add to cart|
- Citations : 0
CDKN1A Antibody (C-term) - Product Information
|Application ||IF, WB, IHC|
|Other Accession||NP_000380.1, NP_510867.1|
|Calculated MW||18119 Da|
CDKN1A Antibody (C-term) - Additional Information
|Gene ID 1026|
CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; p21
This CDKN1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 117-146 amino acids from the C-terminal region of human CDKN1A.
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
CDKN1A Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.
CDKN1A Antibody (C-term) - Protein Information
|Synonyms CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WA|
May be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin- dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D- CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex.
Expressed in all adult tissues, with 5-fold lower levels observed in the brain
CDKN1A Antibody (C-term) - Related Products
CDKN1A Antibody (C-term) - Research Areas
Fluorescent image of A549 cell stained with CDKN1A Antibody (C-term)(Cat#AP13468b).A549 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with CDKN1A primary antibody (1:25, 1 h at 37℃). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37℃).Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37℃).CDKN1A immunoreactivity is localized to Nucleus significantly.
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.
Hu, F., et al. Oncogene 29(40):5464-5474(2010) Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Jiang, P., et al. Acta Biochim. Biophys. Sin. (Shanghai) 42(9):671-676(2010) Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press : Do Nascimento Borges, B., et al. In Vivo 24(4):579-582(2010)